Olaparib Maintenance Improves PFS in BRCA-mutated Ovarian Cancer

Share this content:
Maintenance therapy with single-agent olaparib significantly improved progression-free survival compared with placebo.
Maintenance therapy with single-agent olaparib significantly improved progression-free survival compared with placebo.

Maintenance therapy with single-agent olaparib significantly improved progression-free survival (PFS) compared with placebo among patients with platinum-sensitive relapsed, BRCA-mutated ovarian cancer, according to an announcement by AstraZeneca, the developer of olaparib.1

Results of the phase 3 SOLO-2 trial (ClinicalTrials.gov Identifier: NCT01874353) showed that median PFS with olaparib substantially exceeded that observed in the phase 2 maintenance study among patients with platinum-sensitive relapsed ovarian cancer.

“We are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial," Sean Bohen, executive vice president, global medicines development and chief medical officer at AstraZeneca, said in a press release. "We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer."

The safety profile of olaparib was consistent with previous reports. No new safety signals were observed.

To assess the efficacy of olaparib tablets as maintenance monotherapy compared with placebo, investigators enrolled 295 patients with either germline or somatic BRCA-mutated relapsed or recurrent ovarian cancer who were sensitive to platinum-therapy. Participants had received at least 2 prior lines of platinum-based chemotherapy.

RELATED: Adding Seribantumab to Paclitaxel Fails to Improve PFS in Advanced Ovarian Cancer

Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor approved as monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy.              

Reference

  1. Lynparza phase III SOLO-2 trial shows significant progression-free survival benefit. AstraZeneca website. https://www.astrazeneca.com/media-centre/press-releases/2016/lynparza-phase-iii-solo-2-trial-shows-significant-progression-free-survival-benefit-261020161.html. Updated October 26, 2016. Accessed October 28, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters